Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer

Golf, Alexander; Seipelt, G.; Bauer, Jean; Höhler, T.; Clemens, Michael J.; Löhr, J. M.; Stauch, Martina; Lordick, Florian; Hinke, Axel

doi:10.1200/jco.2004.22.14_suppl.4108

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In pancreatic cancer, 5-FU has been extensively investigated showing small impact on OS and disease control [ 65 ]. Capecitabine, both as a single agent and in combination with other chemotherapeutic agents, has also been evaluated in this tumor type [ 66 , 67 , 68 , 69 , 70 , 71 , 72 ]. Response in terms of clinical benefit is used to evaluate patients with pancreatic cancer due to the palliative nature of therapy and the disease-related symptoms including pain, functional impairment, and anorexia that are often present at later stages.…”

Section: Resultsmentioning

confidence: 99%

“…Responses were mostly PRs and were achieved in 30% to 40% with median survival of 7.5 to 10.5 months [ 70 , 71 ]. In addition, a randomized, multicenter trial comparing capecitabine combinations with either oxaliplatin or gemcitabine with oxaliplatin/gemcitabine in a similar patient population is being conducted as an effort to better define the role of capecitabine in the treatment of pancreatic cancer [ 72 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review

et al. 2008

View full text Add to dashboard Cite

Capecitabine (Xeloda®) was developed as a pro-drug of fluorouracil (FU), with the aim of improving tolerability and intratumor drug concentrations through its tumor-specific conversion to the active drug. The purpose of this paper is to review the available information on capecitabine, focusing on its clinical effectiveness against various carcinomas. Identification of all eligible English trails was made by searching the PubMed and Cochrane databases from 1980 to 2007. Search terms included capecitabine, Xeloda and cancer treatment. Nowadays, FDA has approved the use of capecitabine as a first line therapy in patients with metastatic colorectal cancer when single-agent fluoropyrimidine is preferred. The drug is also approved for use as a single agent in metastatic breast cancer patients who are resistant to both anthracycline and paclitaxel-based regimens or when further anthracycline treatment is contraindicated. It is also approved in combination with docetaxel after failure of prior anthracycline-based chemotherapy. In patients with prostate, pancreatic, renal cell and ovarian carcinomas, capecitabine as a single-agent or in combination with other drugs has also shown benefits. Improved tolerability and comparable efficacy, compared with the intravenous FU/LV combination, in addition to its oral administration, make capecitabine an attractive option for the treatment of several types of carcinomas.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Following on from the earlier phase I/II studies, the combination of gemcitabine with capecitabine has been compared with gemcitabine alone in one randomized phase II (Scheithauer et al 2003a) and two phase III trials (Cunningham et al 2005; Herrmann et al 2005) and also in a randomized phase II trial against gemcitabine plus oxaliplatin (GemOx) and capecitabine plus oxaliplatin (XelOx) (Heinemann et al 2005). …”

Section: Clinical Evidence With Capecitabine In Advanced Carcinoma Ofmentioning

confidence: 99%

“…A further randomized, phase II study compared capecitabine plus gemcitabine (n=50) with gemcitabine plus oxaliplatin (n=57) and capecitabine plus oxaliplatin (n=54) (Heinemann et al 2005). This also showed a trend in favor of the capecitabine-containing arms in terms of response rate and progression-free survival as follows.…”

Section: Clinical Evidence With Capecitabine In Advanced Carcinoma Ofmentioning

confidence: 99%

See 1 more Smart Citation

Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas

Smith

Neoptolemos²

2007

View full text Add to dashboard Cite

Introduction: More than 90% of patients with pancreatic cancer present either with incurable locally advanced or metastatic disease or relapse following surgery. For these patients systemic therapy offers the only prospect of salvage, but pancreatic cancer is one of the most chemoresistant of tumors; current chemotherapy can only delay progression in a limited proportion of patients and survival rates are poor. There is therefore a pressing need for more effective therapy. Capecitabine is a new oral prodrug of fluorouracil, which has shown activity in pancreatic cancer particularly when used in combination with gemcitabine.

show abstract

Pancreatic Cancer

2006

Wiley Handbook of Current and Emerging Drug Therapies

View full text Add to dashboard Cite

show abstract

Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer

Cited by 5 publications

References 0 publications

Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review

Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review

Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas

Pancreatic Cancer

Contact Info

Product

Resources

About